Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-1236 in AML, MDS, and Myelofibrosis
NCT06834282Phase 1Recruiting
- Sponsor
- CERo Therapeutics
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CER-1236 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelofibrosis (MF) (2 arms), sponsored by CERo Therapeutics. Primary endpoints: Incidence of adverse events and serious adverse events at 2 years, Incidence of dose-limiting toxicities at 28 days and 4 more. Started Apr 2025; status: recruiting.
02
Drugs
CER-1236
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06834282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06834282.